Parkinson's Disease

all catalysts(0)

nothing on the calendar yet

News(5)

• MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
  Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
  fiercebiotech · 7d ago
• BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program
  BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather…
  fiercebiotech · 15d ago
• Lilly drops another gene therapy trial from $1B Prevail buyout
  Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
  fiercebiotech · 16d ago
• Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
  Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
  biospace · 17d ago
• Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
  Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
  fiercebiotech · 1mo ago